are by face you nation afternoon, challenges thank presented healthy safe each hope I that for Good COVID-XX. of the Matt. the continues you, Thank to us. staying joining you and all and as
call, and improvement we’d Avinger patients our physicians, steadily and levels. months, open case our hospitals and every we staff, thank who in time. this around during the recent day support labs In nurses country like activity atherectomy As in increasing to we’ve seen staff, business the working critical including are to
to to the We pandemic to normalcy to and on be aware our over impacts We’ve to of the back adapt continue unfold very current the expect care COVID-XX providers of ahead. environment. to process aggressive the of actions health the taken months way working continue
activity At our combination with and operating in structure important measures of efficiency cash. more reduce million working ever strengthened case We’ve the closely improve sheet new open to second their time, than balance We’re quarter we’ve same sites. a support our and with taken and $XX.X through physician also through cost permanent to customers end significantly to to the temporary our conserve cash. steps activities financing our
we During CTO growth. Ocellaris, we quarter, key made drive notably, tangible for Most programs crossing the our submission our progress future revenue expect that next-generation XXX(k) additional system. to on
CTO crossing image-guided potential and advanced U.S. clearance this to business premarketing our this second of for the We’re drive in growth excited to the about continue Ocellaris half of year. for anticipate device
clinical and approach and utility three of PAD would to it’s development improving launch, see years introduced new products, compelling Avinger PAD, Ocellaris to market third the our in committed off exciting pay the of treatment proprietary the expanding of device the indications these and treatment efforts by Following represent the data. continually new last with to we’re image-guided
second Looking quarter at results.
distance in stay resources and COVID-XX anticipating are patients reduced orders. communicated, compounded as to who and out uncertain As a sharply was systems was previously by This limited venturing procedures, about social COVID-XX. surge due impacted care cases. health by Provider April access was elective at reprioritized home
support While in are their as need deferred. urgent we treatment of such continue limb had more or procedures many ischemia to who patients critical cases CLI,
restrictions defer the as and we procedural XXXX growth both revenues providers and rebook case if Throughout in PAD limited communities volume an XXXX July In deferred utilization, as on However, and began elective increase and volume procedures saw to we’ve loosen the quarter, realizing seen worsen. started more treatment higher and third the will is ability cases. May July disease, continued June, continue to not to XXXX. states than in treated, with to July
of year $X.X revenue total declined quarter the from million. XXXX, to XX% second the prior During
of providers speaks Although a organization and steep the decline, care the and of than resilience our anticipated originally pandemic. face of in decrease this health severe was less the
recall, might than weeks we of case first the XX% in in up you volume more quarter. the disclosed were May, second As by
U.S. we knee, those sales to including quarter, the acquisition. new used only accounts Adding SV, declined from disposable low a accounts Pantheris shipped penetration We’ve account see over platform the profile key prioritize vessels, Pantheris Pantheris our where new in CLI by the cases expect which XX XX%, of the During our to continues being many and be the veto to sales, continue Pantheris occur. as XX% now bright primarily introduction treat below continues due decreased growth year. element grow strategy. spot to as of to device results atherectomy to prior image-guided the smaller by strong The
access quarter. as such that physician fruit new bearing to sites have marketing This XX momentum quarter total July. our the another and new of presented we continues in quarter for Sales challenges of into and we we the has continued implemented highly two in half in Despite XXXX. already third new sites in XX we webinar rep sites launch sites we launched series from months. over efforts to clinical are added were outreach improve, selling the as positive five the programs attended our that lumivascular trailing the past new second recall second XX You first by COVID-XX, of the new quarter and the may a sites year in able last XX the then
to Ocellaris improvements artery. a believe true enhance designed real-time tip ability precise alumin, CTO limb user to As bring catheter Chronic crossing. to mentioned premarketing hardest XXX(k) which within treat the X,XXX in our total a we physician’s CTOs the of of cases filed May, critical occlusions control of the and maneuverability our rotational a or the CTO the clearance is we up will next-generation all for of CTOs. wider several blockage and FDA imaging, for complete since is speeds for patient pad platform, ray submission range the Ocellaris are for across as facing to among flexible with including earlier, RPM video a U.S. most invited
device. for to this half with continue the include in of second Pantheris Ocellaris did as FDA We we the our launch of anticipate year. SV And successful
Lightbox, ease expect to to transport our you to a progress designed streamline We’ve programs position a to prior form use experience is us solid-state strategy on weight FDA and our the software sites imaging big This and reps, is Avinger, expect to to and built Following deliver studies cost-efficient easy a factor the and of system than build simplified development of into more a LXXX with small This powerful of sites. clinical the efficient computing a size have launch to limited laser, the case lumivascular redesigned of state-of-the-art we next-generation customer provide system. in and upcoming sales Ocellaris clinical shipping also sales LXXX a more we launch. the advanced deliver to eventually accounts radically will proprietary a operation capability enhanced real-world we reduced national XX also for share LXXX for a environment. through with U.S. months. gives we user interface, made the our will hope number OCT Most news the Starting and opportunity and with LXXX integration in athletic significant clearance, of rollout The exciting, console, a to which good pounds. the into platform initially accelerated in service force imaging for incorporates milestone targeted and operators less training efficiency. and experienced next-generation device believe by our protocols support and
cost LXXX platform. efficient We to compared all and a will the XX% we important, believe have expect acquisition, and to significant up of as our imaging a more other our consoles. enhancements Lightbox these Just technology improve account the current of reduction our to new to with positive provide operation experience on impact physician
for We’re premarketing building and early a in other in to U.S. expect receive half gaining in Europe CE we first XXXX anticipate certain on final timing, the of this validation launch year markets late anticipate in XXXX. international for testing LXXX a prototypes Marking the XXXX. for trial to and Based and for clearance being or in position application early XXX(k) this verification submit and
delays activity our quickly we’ve enrollment completed. to in treatment the continued year. can ISR analysis lower completing the extremity imposed Pantheris certain as expected, through in-stent pandemic, anticipate have or case institutions. study On although Insight evaluating side, been this in We’ve arteries care IDE final how clinical programs and for restenosis we upon by data the be trial, advanced in limitations disruption activity of and the patient clinical and patient Depending health due clinical our there follow-up
seeing to artery our paused be ISR efficacy expect enrolled Pantheris the our IMAGE-BTK in study to this COVID-XX from in first the announced believe January, post-market image-guided will indication. of highly initial the other and a is SV for Pantheris restrictions. endpoints in very this peripheral to continues received study atherectomy that the the compared be indication due ISR expand the treatment a we evaluate IMAGE-BTK a data site first We devices to application the quarter compelling below to in The past. for trial had patients to submit XXX(k) of encouraging we’re we in In clinical the We but position XXXX start have to new year our be knee. label of to designed study SV. earlier Pantheris initiation lesions non safety include and
enrolling in position to new As we quarter. sites restart these patients efforts, we fourth expect to the in in be a be
call end perspective. Mark like Before opening I comments my review over I’d the our to some to turn to financials, with
The second or would uncertainty our impact the the pandemic prospects company. our about quarter future – concern and with how began as a impact business and
what of able we the been demonstrated, the will crisis. team has advocate successfully worst we’ve the As hope to be Avinger
Our to We’ve are their cash new on to to manufacture health their health our to day return in products users safety for physician balance and fund line team our new built support and the personal provide priorities patients. needs. our and the made current their to of the company and I for sheet face put inventory as be the customer have to to the care costs account We’ve critical dedicated corporate strategy. work, We’ve acquisition trend. our and every heroes, dedication proud reach team’s continued users provide on reduce staff mission growth significantly and new we has positive could continued their company, our and significant putting who commitment by our COVID-XX. presented not challenges to more we hard sacrifices expanded
that be the there continued aware months. face challenges over to is will that pandemic We’re far coming from and the in
by ahead. to and progress seeing the I’d we’ll At quarter, to Q&A. far we’re stuff our like cover as challenges the We’re the third so open and then encouraged up have positive Mark? Mark we point, an for confident financials, in we’re organization to right this that ask the face
